$19.66
0.91% day before yesterday
Nasdaq, Jul 11, 10:00 pm CET
ISIN
US14843C1053
Symbol
CSTL

Castle Biosciences Inc Stock price

$19.66
+1.22 6.62% 1M
-6.49 24.82% 6M
-6.99 26.23% YTD
+1.17 6.33% 1Y
-5.38 21.49% 3Y
-21.84 52.63% 5Y
-1.74 8.13% 10Y
-1.74 8.13% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.18 0.91%
ISIN
US14843C1053
Symbol
CSTL
Sector

Key metrics

Basic
Market capitalization
$567.6m
Enterprise Value
$302.8m
Net debt
positive
Cash
$275.2m
Shares outstanding
28.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.6 | 1.9
EV/Sales
0.9 | 1.0
EV/FCF
7.3
P/B
1.3
Financial Health
Equity Ratio
85.8%
Return on Equity
4.0%
ROCE
-3.0%
ROIC
-14.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$347.1m | $300.0m
EBITDA
$25.4m | $-1.2m
EBIT
$-13.8m | $-69.3m
Net Income
$-5.1m | $-70.1m
Free Cash Flow
$41.8m
Growth (TTM | estimate)
Revenue
38.4% | -9.7%
EBITDA
181.4% | -105.7%
EBIT
67.1% | -899.9%
Net Income
83.5% | -484.1%
Free Cash Flow
747.3%
Margin (TTM | estimate)
Gross
81.9%
EBITDA
7.3% | -0.4%
EBIT
-4.0%
Net
-1.5% | -23.4%
Free Cash Flow
12.0%
More
EPS
$-0.2
FCF per Share
$1.4
Short interest
5.0%
Employees
761
Rev per Employee
$440.0k
Show more

Is Castle Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Castle Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Castle Biosciences Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Castle Biosciences Inc forecast:

Buy
93%
Hold
7%

Financial data from Castle Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
347 347
38% 38%
100%
- Direct Costs 63 63
29% 29%
18%
284 284
41% 41%
82%
- Selling and Administrative Expenses 209 209
15% 15%
60%
- Research and Development Expense 50 50
4% 4%
15%
25 25
181% 181%
7%
- Depreciation and Amortization 39 39
268% 268%
11%
EBIT (Operating Income) EBIT -14 -14
67% 67%
-4%
Net Profit -5.07 -5.07
84% 84%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about Castle Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Castle Biosciences Inc Stock News

Neutral
GlobeNewsWire
24 days ago
FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 14, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 66 employees covering an aggregate of 135,978 shares of common stock as an inducement materi...
Neutral
GlobeNewsWire
27 days ago
FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with SciBase Holding AB (“SciBase”) utilizing SciBase's Electrical Impedance Spectroscopy technology which includes both desktop and point-of-care...
Neutral
GlobeNewsWire
about one month ago
FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, founder, president and chief executive officer of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during the 2025 BIO International Convention (...
More Castle Biosciences Inc News

Company Profile

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Head office United States
CEO Derek Maetzold
Employees 761
Founded 2007
Website castlebiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today